

# Facts & Figures



## Global Footprint

17 state-of-the-art  
production facilities  
(incl. 4 Joint Ventures)

15 countries, including all  
major pharma hubs



**€986**

million revenue  
(+5.8% at constant  
currencies)

**€280**

million EBITDA  
Margin: 28.4 %



**>1,300**

patents, patent applications,  
utility models, and designs  
filed by R&D team

**125**

employees  
active in R&D collaborating  
with an exclusive network  
of partners

On average, **more than 30,000 injections per minute**  
are provided to patients worldwide through a SCHOTT Pharma product.

**>13**

billion products  
delivered every year



Glass  
syringes



Polymer  
syringes



Cartridges



Vials



Ampoules



Broad  
ready-to-use  
portfolio



# Market & Customers

The top 30 global pharma companies use SCHOTT Pharma's solutions.

>1,800

customers worldwide



Big pharma innovators



Leading CDMOs



Biotechs & start-ups

## Growth opportunities from structural trends

### GLP-1 drugs

Increasing demand to treat type-2 diabetes, obesity



SCHOTT Pharma has long-term contracts with the leading GLP-1 players

### Antibody-drug conjugates (ADCs)

Innovative ADC therapies need to be lyophilized to ensure drug efficacy



SCHOTT Pharma offers specialty vials that fully eliminate fogging thanks to a hydrophobic inner coating

### Homecare solutions

allow subcutaneous self-injection of small and large drug doses at home, thus reducing healthcare cost



SCHOTT Pharma contributes to fully integrated systems from device manufacturers with primary packaging, e.g. preffillable syringes and cartridges in small and large formats

### Manufacturing transformation

Smaller patient populations require more flexible filling lines



SCHOTT Pharma offers pre-sterilized, ready-to-use products for utmost flexibility



# ESG Responsibility



**60%**

reduced CO<sub>2</sub>  
emissions since 2019<sup>1</sup>

**100 %**

Already using green  
electricity worldwide



Closed-loop  
recycling pilot  
projects started  
e.g. polymer trays for  
vials

Vials with reduced product  
carbon footprint  
available from 2027<sup>2</sup>



**~4.800**

employees from over

**>65**

nationalities

**>40%**

female employees

**~23 %**

of leadership positions  
held by women



## Ownership

Carl Zeiss  
Foundation



Carl Zeiss AG  
Oberkochen

SCHOTT

SCHOTT AG  
Mainz

SCHOTT  
PHARMA

SCHOTT Pharma  
AG & Co. KGaA  
Mainz

## Executive Board



**Andreas Reisse**  
CEO

Over 35 years of experience

Heading SCHOTT's pharma  
business since 2010

Previously headed SCHOTT's  
Tubing business unit

Master's Degree in Industrial  
Engineering



**Reinhard Mayer**  
CFO

Over 30 years of experience

CFO of SCHOTT Pharma since 2025

Previous CFO roles with Nilfisk  
Holding, Hansgrohe, and Getinge  
Group

Master's Degree in Industrial  
Engineering

<sup>1</sup> Scope 1 & 2; Defined as corporate CO<sub>2</sub> footprint of SCHOTT Pharma divided by number of good pieces sold (as of FY 2022)

<sup>2</sup> Approximately 30% CO<sub>2</sub> reduction for a 2 ml vial compared to current technology



# SCHOTT Pharma's Governance

**KGaA** (Kommanditgesellschaft auf Aktien) is a listed partnership limited by shares with three corporate bodies:



**General partner**  
(Komplementär)



**Supervisory board**  
(Aufsichtsrat)



**General shareholders' meeting**  
(Hauptversammlung)

As a **popular legal form** for companies originating from families or foundations, there are many **established KGaA** in Germany.

## Supervisory Board

Shareholder representatives



**Chairman**  
Peter Goldschmidt  
CEO  
Stada AG



**Deputy Chairman**  
Dr. Wolfram Carius  
Executive Vice President  
Bayer AG



Eva Kienle  
CFO  
KWS Saat SE & Co. KGaA



Ann-Kristin Erkens  
CFO  
SIG Group AG

## Employee representatives



Mario Just  
SCHOTT Pharma



Isabel Deister  
SCHOTT Pharma

## Press contact



**Lea Kaiser**



[lea.kaiser@schott.com](mailto:lea.kaiser@schott.com)



+49 (0) 151/68 91 71 95



**Katrin Schreyer**



[katrin.schreyer@schott.com](mailto:katrin.schreyer@schott.com)



+49 (0) 171/11 67 54 4

